Lunit Inc. announced two supply contracts that mark its strategic expansion into the East and Southeast Asian region. Lunit will supply its Lunit INSIGHT CXR for chest abnormality detection and Lunit INSIGHT MMG for mammography analysis to the Chung Shan Medical University in Taiwan and Gleneagles Hospital in Singapore, respectively. Under the newly inked supply contract, Lunit will collaborate with the prestigious Chung Shan Medical University (CSMU), Taiwan's leading medical university.

This collaboration holds the potential to revolutionize Taiwan's national lung cancer screening program. Compared to Taiwan's current screening program, which relies on low-dose computed tomography (LDCT) for screening high-risk individuals such as smokers or those with a family history of lung cancer, CSMU aims to validate Lunit INSIGHT CX RXR for potential integration into the national cancer screening program. The goal is to assess its ability to detect individuals more accurately and efficiently, potentially expanding the screening to a broader group beyond high-risk individuals.

This approach could significantly advance Taiwan's efforts to enhance early detection and improve outcomes in lung cancer screening. In a parallel move, Lunit is set to deliver its AI-powered mammography analysis solution, Lunit INSIGHT MMG, to Gleneagles Hospital in Singapore. Gleneagles Hospital, part of Southeast Asia's largest medical group, IHH, is a leading private healthcare provider in the region.

Recognized with the Singapore Quality Class certification, the hospital offers extensive clinical facilities with 221 beds, emphasizing its commitment to exceptional standards in healthcare.